Nicaragua continues negotiations for CoviVac and Sputnik Light production
By Guy José Bendaña-Guerrero & Asociados
The Government of Nicaragua announced that it will "soon" begin to produce Russian vaccines CoviVac and Sputnik Light, with the support of the Scientific Research Institute of Vaccines and Sera of Saint Petersburg.CoviVac is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Center, which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It obtained a permission for phase III clinical trial on 2 June 2021.
Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine.
In August 2020, a team of Nicaragua state officials met with Victor Trujin, director of the Scientific Research Institute of Vaccines and Sera of Saint Petersburg, and with Stanislav Uiba, manager of the Latin American Institute of Biotechnology Mechnikov, based in Managua.
At the meeting, the parties exchanged on the role of Nicaragua in Russian vaccines distribution and possible production.
